ArticleBlood cancer discovery2021
Open access · greenAbstract read
In one paragraph
Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.The Journal of clinical investigation · 2026Article
- Loss of Y chromosome in Alzheimer's patients co-occurs with somatic mutations beyond CHIP drivers.Life science alliance · 2026Article
- Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations.Nature communications · 2025Article
- Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes.medRxiv : the preprint server for health sciences · 2025Article
- Mtg16 NHR1 mutations cause defects in lymphopoiesis and the response to anemia.Experimental hematology · 2025Article
- Kaiso mediates transcription and RNA splicing in colorectal carcinoma: role of BRCA1 in the Kaiso enhanceosome.Open biology · 2025Article
- Clonal hematopoiesis: elements associated with clonal expansion and diseases.Blood research · 2025Review
- Biomarkers in clonal haematopoiesis of indeterminate potential (CHIP) linking cardiovascular diseases, myeloid neoplasms and inflammation.Annals of hematology · 2025Review
- Clonal hematopoiesis in large granular lymphocytic leukemia.Leukemia · 2025Article
- SUMOylation of TRIM28 is positively modulated by the BTB/POZ domain of Kaiso.Molecular biology reports · 2025Article
- Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes.HemaSphere · 2025Article
- Dissecting the Kaiso binding profile in clear renal cancer cells.Epigenetics & chromatin · 2024Article
- Article
- The Genetic Determinants and Genomic Consequences of Non-Leukemogenic Somatic Point Mutations.medRxiv : the preprint server for health sciences · 2024Article
- The Clonal Hematopoiesis-associated GenebioRxiv : the preprint server for biology · 2024Article
- Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis.Nature genetics · 2024Article
- Article
- Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis.Nature genetics · 2023Article
- SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation.Cell stem cell · 2023Article
- Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 13 institutions in 4 countries.
Ellen M BeauchampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Matthew LeventhalDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Elsa BernardDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2057-7187
Emma R HoppeComputational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-8544-9055
Gabriele TodiscoDepartment of Molecular Medicine, University of Pavia, and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0001-6583-3829
Maria CreignouCenter for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-7629-0871
Anna GallìDepartment of Molecular Medicine, University of Pavia, and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0002-4039-3756
Cecilia A CastellanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Marie McConkeyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Akansha TarunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Waihay WongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-2023-6590
Monica SchenoneBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0002-6456-8768
Caroline StancliftBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0002-9208-8550
Benjamin TanenbaumBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Edyta MalolepszaBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Björn NilssonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Alexander G BickBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0001-5824-9595
Joshua S WeinstockCenter for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan.
Mendy MillerBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Abhishek NiroulaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Andrew DunfordBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Amaro Taylor-WeinerBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Timothy WoodBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Alex BarberaBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Shankara AnandBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0003-4514-0835
Bruce M PsatyCardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, Washington.
Pinkal DesaiDivision of Hematology and Oncology, Weill Cornell Medical College, New York, New York.
Michael H ChoDivision of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Andrew D JohnsonNational Heart, Lung, and Blood Institute Center for Population Studies, the Framingham Heart Study, Framingham, Massachusetts.
Ruth LoosThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium
Daniel G MacArthurBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Monkol LekBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Exome Aggregation Consortium
Donna S NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-2566-3145
Kasper LageBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Steven A CarrBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0002-7203-4299
Eva Hellstrom-LindbergCenter for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Luca MalcovatiDepartment of Molecular Medicine, University of Pavia, and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Elli PapaemmanuilDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Chip StewartBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0003-2245-9552
Gad GetzBroad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0002-0936-0753
Robert K BradleyComputational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-8046-1063
Siddhartha Jaiswal *Department of Pathology, Stanford University School of Medicine, Stanford, California. Benjamin_ebert@dfci.harvard.edu sjaiswal@stanford.edu.
Benjamin L Ebert *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Benjamin_ebert@dfci.harvard.edu sjaiswal@stanford.edu.
Broad Institute · USKarolinska University Hospital · SEMemorial Sloan Kettering Cancer Center · USUniversity of Pavia · ITUniversity of Washington · USBrigham and Women's Hospital · USChild Health and Development Institute · USCornell University · USDana-Farber Cancer Institute · USFramingham Heart Study · USKaiser Permanente Washington Health Research Institute · USStanford University · USUniversity of Michigan · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MGenetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9MTYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5MGenetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7MIDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MMolecular, Cellular, & Developmental Dynamics PhD ProgramT32GM007226 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI VAN VACTOR, DAVID L. · 1985 to 2021
$14.4MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MStudies of Rare Genetic Variation in the Isolated Population of SardiniaR01HL117626 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABECASIS, GONCALO · 2013 to 2016
$10.5MTyrosine Kinases, Serine-Threonine Kinases,&Phosophatases in PathogenesisP01CA108631 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ESTEY, ELIHU · 2005 to 2009
$9.7MExceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5MRare variants and NHLBI traits in deeply phenotyped cohortsR01HL120393 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M, RICE, KENNETH M. · 2014 to 2016
$8.9MNCI NIH HHS P01 CA066996NCI NIH HHS P01 CA108631NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA251138NCI NIH HHS R35 CA253125NHGRI NIH HHS T32 HG002295NHGRI NIH HHS U01 HG007417NHLBI NIH HHS DP2 HL157540NHLBI NIH HHS F31 HL143844NHLBI NIH HHS HHSN268200800007CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS HHSN268201500014CNHLBI NIH HHS HHSN268201600001CNHLBI NIH HHS HHSN268201600002CNHLBI NIH HHS HHSN268201600003CNHLBI NIH HHS HHSN268201600004CNHLBI NIH HHS HHSN268201600018CNHLBI NIH HHS HHSN268201800001CNHLBI NIH HHS N01 HC025195NHLBI NIH HHS N01 HC055222NHLBI NIH HHS N01 HC085079NHLBI NIH HHS N01 HC085080NHLBI NIH HHS N01 HC085081NHLBI NIH HHS N01 HC085082NHLBI NIH HHS N01 HC085083NHLBI NIH HHS N01 HC085086NHLBI NIH HHS R01 HL082945NHLBI NIH HHS R01 HL092577NHLBI NIH HHS R01 HL117626NHLBI NIH HHS R01 HL120393NHLBI NIH HHS R01 HL128239NHLBI NIH HHS R01 HL148565NHLBI NIH HHS R01 HL151651NHLBI NIH HHS U01 HL080295NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897NHLBI NIH HHS U01 HL130114NIA NIH HHS R01 AG023629NIDDK NIH HHS R01 DK103854NIEHS NIH HHS HHSN268201600032CNIEHS NIH HHS HHSN268201600033CNIGMS NIH HHS T32 GM007226
Abstract
Clonal hematopoiesis results from somatic mutations in cancer driver genes in hematopoietic stem cells. We sought to identify novel drivers of clonal expansion using an unbiased analysis of sequencing data from 84,683 persons and identified common mutations in the 5-methylcytosine reader,
Indexed as
Clonal HematopoiesisMyelodysplastic SyndromesAnimalsHematopoiesisHematopoietic Stem CellsHumansMiceRNA SplicingTranscription FactorsTranscription FactorsZbtb33 protein, mouseclonal hematopoiesishematologic malignancieshematopoietic stem cellsmyeloid neoplasiasomatic driver gene discovery
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.